<DOC>
	<DOCNO>NCT01645839</DOCNO>
	<brief_summary>The purpose study compare neurological progression free survival use intrathecal chemotherapy liposomal cytarabine ( DepoCyte® ) leptomeningeal metastasis breast cancer ( versus intrathecal treatment ) .</brief_summary>
	<brief_title>Interest Intrathecal Chemotherapy With Liposomal Cytarabine ( DepoCyte® ) Meningeal Metastasis Breast Cancer</brief_title>
	<detailed_description>Patients eligible trial sign consent participate randomize arm A B . - Arm A : Standard systemic treatment without Depocyte® - Arm B : Standard systemic treatment Depocyte® Patients randomize arm B receive intrathecal injection Depocyte® every 14 ± 2 day total 5 cycle every 28 day progression . The treatment begin day follow randomization ( maximum 10 day ) . The nature standard systemic treatment ( chemotherapy , hormone therapy target therapy ) leave discretion investigator accord subtype breast cancer accord treatment already receive . It determine prior randomization . It amend time upon notice patient 's referent oncologist . A focal radiotherapy symptomatic site also perform necessary . Patients : - clinical assessment within 3 day prior start study treatment , every 2 week 2 month , month progression , end study ; - paraclinical assessment within 14 day prior start study treatment , every 2 month , end study ; - biologic assessment within 7 day prior start study treatment , month progression , end study . They likewise undergo lumbar puncture prior start treatment , month patient arm A , every 2 week 2 month , month progression patient arm B finally end study . They also address questionnaire within 3 day prior start study treatment , every 2 week 2 month , month progression end study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically confirm invasive breast cancer . New diagnosis leptomeningeal involvement confirm CSF cytology clinical sign symptom associate abnormal MRI feature . MRI criterion : meningeal metastasis &lt; 0.5 cm &gt; 0.5 cm case focus radiation therapy . Patient require systemic treatment ( chemotherapy / target therapy / hormone therapy ) time inclusion . The systemic treatment leave discretion investigator connection referent senologist accord characteristic cancer , previous treatment receive clinical biological general state . Focused radiotherapy authorize . Age ≥ 18 year Performance Status ( ECOG ) ≤ 2 . Patients unable walk due paralysis move wheelchair consider ambulatory . Life expectancy &gt; 2 month . Patients rapidly progressive systemic disease eligible protocol . Brain metastasis allow asymptomatic . In case suspicion CSF blocking , local radiotherapy lift CSF blocking , study flow CSF perform ( isotopic method ) confirm absence CSF flow block . Patients must recover acute toxic effect cancer treatment receive . Adequate hematological , renal , hepatic parameter : Total bilirubin ≤ 3 time upper limit normal ( ULN ) . SGOT/AST ≤ 2.5 ULN ; ≤ 5 ULN hepatic metastasis Effective contraceptive method ( CPMP/ICH/286/95 ) non menopausal patient ( eg intrauterine device ( IUD ) , sexual abstinence , vasectomized partner ) ( hormonal contraception ) . Patients social security scheme . Informed consent form sign patient . Leptomeningeal metastasis breast cancer . History cancer ( &lt; 5 year ) except cervix carcinoma , basal cell squamous cell skin carcinoma properly treat . Contraindication MRI ( include claustrophobia ) MRI criterion : CSF flow obstruction ( hydrocephalus brain MRI obstacle spinal MRI ) Contraindication lumbar puncture ventricular catheterization . Progressive brain metastasis require total brain radiation therapy . History craniospinal radiotherapy ( History focal whole brain radiation therapy parenchymal metastasis accept ) . History intrathecal treatment ( lumbar ventricular ) . History systemic treatment ARAC highdose systemic methotrexate . Intravenous high dose concomitant treatment methotrexate . Ventriculoperitoneal shunt . Active infection ( systemic cerebromeningeal ) . Hypersensitivity ARAC DepoCyte . Other severe non control pathology could jeopardize participation trial ( infection , cardiovascular , digestive , renal , pulmonary disease ) . Patient already include another therapeutic trial experimental molecule ( within 30 day screen visit ) . Pregnant breastfeed woman . Women must breastfeed least 6 month . Patients unable undergo medical follow geographic , social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Leptomeningeal metastasis</keyword>
	<keyword>Intrathecal chemotherapy</keyword>
	<keyword>Depocyte</keyword>
</DOC>